HeartBeam Inc. (NASDAQ: BEAT) has reported its second-quarter 2026 financial and operational results, showcasing notable advancements in its heart attack detection program and commercial launch efforts. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, it surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, underscoring the progress in validating its technology for detecting heart attacks.
HeartBeam also completed a working prototype of its 12-lead ECG extended wear patch, a key milestone in expanding its product portfolio. The company has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, marking the beginning of its commercial rollout. These developments are critical as HeartBeam aims to transform cardiac care by enabling patients to capture ECG signals in 3D using a cable-free device that synthesizes a 12-lead ECG, potentially allowing for earlier detection of cardiac events.
The company reported a second-quarter net loss of $5 million, or $0.10 per share, consistent with the prior year's loss of $5 million, or $0.15 per share. Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. HeartBeam expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, extends its runway into 2027. This financial stability is crucial for a company in the clinical and commercial stages, providing the resources needed to continue its studies and expand its market presence.
The significance of these results lies in the potential of HeartBeam's technology to address a critical gap in cardiac care. Traditional ECGs are often performed in medical facilities, but HeartBeam's portable device allows for ECG recording in any setting, potentially enabling earlier detection of heart attacks and other cardiac conditions. The completion of the ALIGN-ACS pilot study and the progress in HEADSTART-ACS bring the company closer to regulatory approvals and broader clinical adoption. Moreover, the initial commercial agreements and shipments indicate that HeartBeam is transitioning from a development-stage company to a commercial entity, which could have substantial implications for patient outcomes and the company's growth trajectory.
Investors and stakeholders can access the full press release for more details at https://ibn.fm/QjrtT. HeartBeam's technology has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis software, and the company holds over 20 issued patents. These milestones, combined with the company's financial management, position HeartBeam as a key player in the evolving landscape of remote cardiac monitoring.
